<DOC>
	<DOCNO>NCT01414296</DOCNO>
	<brief_summary>Prostate-specific Membrane Antigen Antibody-Drug Conjugate ( PSMA ADC ) 1301EXT open-label , nonrandomized , phase 1 extension study PSMA ADC administer IV subject progressive CMPC progress prior taxane therapy . Subjects participate PSMA ADC 1301 , opinion PI , likely benefit continue treatment PSMA ADC enrol PSMA ADC 1301EXT .</brief_summary>
	<brief_title>Extended Study Prostate-specific Membrane Antigen Antibody-Drug Conjugate Subjects With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Subjects complete PSMA ADC 1301 study , opinion investigator , derive benefit treatment PSMA ADC . 2 . A diagnosis progressive , castrationresistant , metastatic prostate cancer . 3 . Prior chemotherapy regimen , one contain taxane . 4 . Eastern Cooperative Oncology Group status 0 1 1 . Clinically significant cardiac disease severe debilitation pulmonary disease 2 . Evidence active infection require ongoing antibiotic therapy 3 . History drug and/or alcohol abuse</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>